Michael Alonso

Michael Alonso

Company: Bolt Biotherapeutics

Job title: Vice President of Immunology & Pharmacology


PD-L1 ISACs elicit superior anti-tumor activity over PD-L1 mAbs: the benefit of ISAC-driven phagocytosis and direct activation of PD-L1-expressing myeloid cells 2:30 pm

Overview of Bolt’s Immune-Stimulating Antibody Conjugates (ISAC) technology platform as the next step in ADC-based immune therapy Highlighting the key features and the mechanism of action Demonstrating the use of various methods to understand and design potent ISACsRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.